Biotechnology company developing therapies for endocrine diseases, including oral small-molecule candidates for Prader-Willi syndrome, congenital adrenal hyperplasia, and Cushing’s syndrome
Biotechnology company developing therapies for endocrine diseases, including oral small-molecule candidates for Prader-Willi syndrome, congenital adrenal hyperplasia, and Cushing’s syndrome. Search results also associate the Millendo name with clinical-stage oncology programs targeting PPAR and EP2/EP4 pathways; these may reflect a later company or changed portfolio.